Rights to Common Stock Under BD Deferred Compensation PlanDerivative
Shares+105
Price$149.04
Total Value$15.6K
Shares Owned After3.70K
Transaction DateMay 8, 2026
Footnotes ▸
The securities convert to common stock on a one-for-one basis. | The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. | The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person. | Includes rights acquired through dividend reinvestment since the last report filed by the reporting person. | Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person.
Post-Transaction Holdings
Byington Carrie L
Security
Shares
Change
Rights to Common Stock Under BD Deferred Compensation Plan
3.70K
+105 (2.92%)
Original SEC Filing Textexpand_more
=== SEC Form 4 — Statement of Changes in Beneficial Ownership ===
Document Type: 4
Period of Report: 2026-05-08
10b5-1 Pre-arranged Plan: No
--- Issuer ---
Name: BECTON DICKINSON & CO (BDX)
CIK: 0000010795
--- Reporting Owner ---
Name: Byington Carrie L
CIK: 0001890265
Role: Director
--- Derivative Transactions ---
[Transaction #1]
Security: Rights to Common Stock Under BD Deferred Compensation Plan
Date: 2026-05-08 | Code: A (Grant or award)
Shares: +105 | Price: $149.04
Shares Owned After: 3,699 | Ownership: D (Direct)
Footnotes:
[F1] The securities convert to common stock on a one-for-one basis.
[F2] The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.
[F2] The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.
[F3] Includes rights acquired through dividend reinvestment since the last report filed by the reporting person.
[F4] Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person.
--- Footnotes (Complete Index) ---
F1: The securities convert to common stock on a one-for-one basis.
F2: The securities are distributed following termination of the reporting person's service as a director, or on the date or dates specified by the reporting person.
F3: Includes rights acquired through dividend reinvestment since the last report filed by the reporting person.
F4: Reflects the adjustments made in connection with the combination of the Biosciences and Diagnostic Solutions businesses with Waters Corp. to the number of previously reported derivative securities held by the reporting person.
--- Signature ---
/s/ Donna Kalazdy, by power of attorney for Carrie L Byington (2026-05-08)
